

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TenNor Therapeutics (Suzhou) Limited

丹諾醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6872)

NOTICE OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Director(s)**”) of TenNor Therapeutics (Suzhou) Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, August 26, 2026 for the purposes of, among other matters, considering and approving the interim results of the Company and its subsidiaries for the six months ended June 30, 2026 and its publication and considering the payment of an interim dividend, if any.

By order of the Board
TenNor Therapeutics (Suzhou) Limited
Dr. Ma Zhenkun
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, August 14, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ma Zhenkun as an executive Director; (ii) Dr. Song Gaoguang as a non-executive Director; and (iii) Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping as independent non-executive Directors.